Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer

被引：1
|
作者：
Saatci, Ozge
Gedik, Mustafa Emre
Oberholtzer, Nathaniel
Uner, Meral
Akbulut, Ozge
Cetin, Metin
Aras, Mertkaya
Ibis, Kubra
Caliskan, Burcu
Banoglu, Erden
Wiemann, Stefan
Uner, Aysegul
Aksoy, Sercan
Mehrotra, Shikhar
Sahin, Ozgur
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB275
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB275
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer
    Gedik, Mustafa Emre
    Saatci, Ozge
    Oberholtzer, Nathaniel
    Uner, Meral
    Caliskan, Ozge Akbulut
    Cetin, Metin
    Aras, Mertkaya
    Ibis, Kubra
    Caliskan, Burcu
    Banoglu, Erden
    Wiemann, Stefan
    Uner, Aysegul
    Aksoy, Sercan
    Mehrotra, Shikhar
    Sahin, Ozgur
    CANCER RESEARCH, 2024, 84 (09) : 1475 - 1490
  • [2] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [3] mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
    Casadevall, David
    Hernandez-Prat, Anna
    Garcia-Alonso, Sara
    Arpi-Llucia, Oriol
    Menendez, Silvia
    Qin, Mengjuan
    Guardia, Cristina
    Morancho, Beatriz
    Sanchez-Martin, Francisco Javier
    Zazo, Sandra
    Gavilan, Elena
    Sabbaghi, Mohammad A.
    Eroles, Pilar
    Cejalvo, Juan Miguel
    Lluch, Ana
    Rojo, Federico
    Pandiella, Atanasio
    Rovia, Ana
    Anabell, Joan
    MOLECULAR CANCER RESEARCH, 2022, 20 (07) : 1108 - 1121
  • [4] RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM)
    Berghoff, A. S.
    Bartsch, R.
    Bergen, E.
    Rudas, M.
    Gnant, M.
    Dieckmann, K.
    Pinker, K.
    Zielinski, C. C.
    Steger, G. G.
    Preusser, M.
    NEURO-ONCOLOGY, 2014, 16
  • [5] T-DM1 for residual, invasive, HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2019, 20 (01): : E13 - E13
  • [6] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [7] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [8] Activity of T-DM1 in HER2-positive breast cancer brain metastases
    Bartsch, Rupert
    Berghoff, Anna S.
    Vogl, Ursula
    Rudas, Margaretha
    Bergen, Elisabeth
    Gnant, Michael
    Dieckmann, Karin
    Pinker, Katja
    Bago-Horvath, Zsuzsanna
    Galid, Arik
    Oehler, Leopold
    Zielinksi, Christoph C.
    Steger, Guenther G.
    Preusser, Matthias
    CANCER RESEARCH, 2015, 75
  • [9] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [10] Activity of T-DM1 in HER2-positive breast cancer brain metastases
    Bartsch, R.
    Berghoff, A. S.
    Rudas, M.
    Bergen, E.
    Gnant, M.
    Dieckmann, K.
    Pinker, K.
    Zielinski, C. C.
    Preusser, M.
    Steger, G. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S184 - S184
12345